Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bassia scoparia pollen is an allergenic extract derived from the pollen of the *Bassia scoparia* plant (formerly known as *Kochia scoparia*), commonly referred to as firebush or Mexican fireweed. This biologic product is primarily utilized as a diagnostic reagent in skin testing (percutaneous or intradermal) to confirm sensitization in patients suspected of having Type I hypersensitivity to this weed pollen. The extract works by cross-linking allergen-specific IgE antibodies bound to the surface of mast cells and basophils, triggering the release of inflammatory mediators like histamine, which results in a characteristic wheal-and-flare reaction. In addition to its diagnostic role, the extract is used in allergen immunotherapy (AIT) to desensitize patients and reduce symptoms of allergic rhinitis and asthma. It is manufactured by companies such as Allermed Laboratories, Greer Laboratories, and ALK-Abelló.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Bassia scoparia pollen.